COVonco Study

Join the COVonco study and help understand the impact of COVID-19 in oncology

Collaborate with us!
This study has a multicentric approach. Those interested in participating in the research can contact the Study Coordinator directly.

Why study COVID-19 in cancer patients?
Cancer patients seem to be particularly susceptible to morbilities and mortality by this disease (1,2,3). Moreover, the first studies in cancer patients suggested an increase in the risk to get this viral infection and develop complications related to COVID-19 (4,5,6,7,8). It should also be taken into consideration that several studies remark the high mortality by COVID-19 in cancer patients (8,9,10).

How can this study be useful?
This study aims to establish preventive strategies in oncologic patients, especially in the case of receiving immunosuppressive chemotherapy. The results could be useful to help doctors in informed debates about the risk of COVID-19 and allow a focus based on evidence of national policies of social isolation.

Description of the Study:

  • Title: Diagnosis and serologic follow-up of COVID-19 in oncologic patients (COVonco).
  • Principal Investigator: Cristina Royo-Cebrecos.
  • Co-Investigators: Irene Ambatlle, Ïa Montaner, Eva Mahía, Jaume Pujadas Francesc Cobo, Santiago Albiol.
  • Centers of Implementation: the pilot center will be the Servei Andorrà de Salut Sanitària (SAAS). This study is open to collaborations from other centers.
  • Study Population: adult patients with an oncologic disease under follow-up by the Service of Oncology or Haematology in a 5-year period (2016-2020) that have a serological test for SARS-CoV-2. From these patients, a subgroup of patients with active oncological treatment will be selected.
  • Study Type: observational, cohort, multicentric, prospective study.

Objetives of the Study:

  • Principal Objective: Compare the prevalence of SARS-CoV-2 between groups of the oncologic population depending on the type of treatment: chemotherapy, immunotherapy, radiotherapy, and oncologic population without active treatment.
  • Secondary Objectives:
    (1) Assess the serologic response over time in a follow-up period of 3, 6, and 12 months.
    (2) Identify the incidence of asymptomatic infection in the oncologic population and detection of seroconversion.
    (3) Estimate the percentages of active infection (positive PCR) among cancer patients with a positive IgM test.
    (4) Estimate the global seroprevalence of SARS-CoV-2 of cancer patients.
    (5) Identify the diagnostic follow-up of SARS-CoV-2 of cancer patients.
    (6) Identify how the management of the oncologic disease changes in case of a positive diagnosis of SARS-CoV-2.
The SAAS leads the COVonco study to help understand the impact of COVID-19 in oncology.

Other Studies about Serology:

Effectiveness of vaccine combination

Científicos franceses demuestran que la vacunación primaria con dos vacunas diferentes sería más eficaz que la vacunación con dos vacunas idénticas.

COVID-19 immunity in healthcare professionals

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19…

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the…

Mass SARS-CoV-2 Serological Screening in Andorra

This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality…


SAPRIS-SERO is a study to estimate the seroprevalence of SARS-CoV-2 infection in the epidemiological cohorts Constances, E3-E4N, NutriNet-Santé and Elfe-Epipage2 in France.


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical…


The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a…


The EpiCOV project aims to provide a global and scientifically reliable mapping of the immune status of the population in France through serological tests and…

REACT-2.5: Seroprevalence of SARS-CoV-2 antibodies

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.